ArticleBMJ (Clinical research ed.)1998
Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study.
Article in BMJ (Clinical research ed.), 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 119 citations in OpenAlex.
- Neutrophil Elastase, Neuron-Specific Enolase, and S100B Protein as Potential Markers of Long-Term Complications Caused by COVID-19 in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Stage of Diabetic Nephropathy (NfT2DM)-Observational Studies.International journal of molecular sciences · 2024Observational
- Review
- Development of prognostic models for survival and care status in sporadic Creutzfeldt-Jakob disease.Brain communications · 2022Article
- Sporadic Creutzfeldt-Jakob disease: Real-Time Quaking Induced Conversion (RT-QuIC) assay represents a major diagnostic advance.European journal of histochemistry : EJH · 2021Review
- Review
- Liquid Diagnosis of Hepatic Encephalopathy: Are We There Already?GE Portuguese journal of gastroenterology · 2020Article
- Challenges and Advances in Antemortem Diagnosis of Human Transmissible Spongiform Encephalopathies.Frontiers in bioengineering and biotechnology · 2020Review
- Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease.Scientific reports · 2016Article
- Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study.PloS one · 2012Article
- cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.International journal of Alzheimer's disease · 2010Article
- Application of "omics" to prion biomarker discovery.Journal of biomedicine & biotechnology · 2010Review
- Youden Index and the optimal threshold for markers with mass at zero.Statistics in medicine · 2008Article
- Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology.Journal of virology · 2004Article
- Article
- S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner.Molecular and cellular biology · 2003Article
- Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy.Metabolic brain disease · 1999Article
- Diagnosis of Creutzfeldt-Jakob disease. Routine tonsil biopsy for diagnosis of new variant Creutzfeldt-Jakob disease is not justified.BMJ (Clinical research ed.) · 1999Article
- Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum. Appropriate study populations must be used.BMJ (Clinical research ed.) · 1998Article
- Early identification of variant Creutzfeldt-Jakob disease.BMJ (Clinical research ed.) · 1998Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyse serum concentrations of brain specific S100 protein in patients with Creutzfeldt-Jakob disease and in controls.
designProspective case-control study.
settingNational Creutzfeldt-Jakob disease surveillance unit. SUBJECTS: 224 patients referred to the surveillance unit with suspected Creutzfeldt-Jakob disease and 35 control patients without dementia.
main outcome measureSerum concentration of S100 protein in patients with Creutzfeldt-Jakob disease, in patients with other diseases causing dementia, and in the control group.
resultsOf the 224 patients with suspected Creutzfeldt-Jakob disease, 65 were classed as definitely having the disease after neuropathological verification, an additional 6 were classed as definitely having the disease as a result of a genetic mutation, 43 as probably having the disease, 36 as possibly having the disease, and 74 patients were classed as having other disease. In the 108 patients classed as definitely or probably having Creutzfeldt-Jakob disease the median serum concentration of S100 was 395 pg/ml (SD 387 pg/ml). This was significantly higher than concentrations found in the 74 patients classed as having other diseases (median 109 pg/ml; SD 177 pg/ml; P = 0.0001). At a cut off point of 213 pg/ml sensitivity for the diagnosis of the disease was 77.8% (95% confidence interval 68.8% to 85.2%) and specificity was 81.1% (70.3% to 89.3%). There was a significant difference in survival at different concentrations of S100 in Kaplan-Meier curves (P = 0.023).
conclusionMeasurement of serum concentrations of S100 is a valuable tool which can be used more easily than tests on cerebrospinal fluid in the differential diagnosis of Creutzfeldt-Jakob disease. More studies are needed to determine whether serial testing of serum S100 improves diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.